The content on this site is intended for healthcare professionals only
Results from the phase I ICONIC trial
Economic impact of NGS in non small cell lung cancer
Avelumab in combinations for lung cancer and update from ALEX study
Early results from a 3rd gen EGFR-TKI in advanced NSCLC
Pembrolizumab works better than chemotherapy alone as initial treatment for NSCLC
Comment: PD-1 immunotherapy better than chemo alone as first line lung cancer treatment
PD-1 immunotherapy better than chemo alone as first line lung cancer treatment
Web-mediated follow-up via patient-reported outcomes vs. routine surveillance in lung cancer patients
Development of blood tests for early lung cancer
Atezolizumab with chemotherapy improves PFS in squamous NSCLC
Development of blood tests for early lung cancer
Atezolizumab with chemotherapy improves PFS in squamous NSCLC
